---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-277478"
form_type: "8-K"
ticker: "RVTY"
cik: "0000031791"
company_name: "REVVITY, INC."
filed_at: "2021-09-21T23:59:59+00:00"
generated_at: "2026-06-29T02:26:33.895413+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# PerkinElmer closes $5.25B BioLegend acquisition; issues ~14.1M shares as stock consideration

## Summary
- Aggregate purchase price ~$5.25B; paid 59.5% cash and 40.5% stock valued at $156.3561/share.
- Cash funded by $2.28B notes offering, $500M term loan draw, ~$300M revolver draw, and cash on hand.
- Transaction closed on September 17, 2021; previously announced on July 25, 2021.
- Issued 14,066,771 shares of common stock in a private placement to BioLegend stockholders.
- Financial statements and pro forma information to be filed by amendment within 71 days.

## SEC filing metadata
- accession: 0001193125-21-277478
- form_type: 8-K
- ticker: RVTY
- cik: 0000031791
- company_name: REVVITY, INC.
- filed_at: 2021-09-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/31791/000119312521277478/0001193125-21-277478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/31791/000119312521277478/d233653d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-277478
- JSON: https://secwatch.observer/filing/0001193125-21-277478.json
- Plain text: https://secwatch.observer/filing/0001193125-21-277478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.